Researchers from the State University of Washington have come up with number of new candidate drugs that are capable to reduce the desire to consume nicotine among the smokers. These drugs help in slowing down the way nicotine is broken down in the body. The focus of the researchers is to minimize the consumption of tobacco, even if they cannot quit it altogether.
The study published in journal of Medical Chemistry, aiming a liver enzyme, known as CYP2A6, which metabolizes nicotine. According to Canadian researchers, research done in mid-90s suggest that people who have fewer copies of a gene are expected to smoke less and are less likely to get addicted to smoking.
Body releases two chemicals namely serotonin and dopamine that are activated by consuming nicotine. However, as it settles in the body, the person experience withdrawal symptoms such as seating, irritability, anxiety, and tingling in hands and feet.
Assistant professor of pharmaceuticals science and lead author, Travis Denton states that these are the feeling the researchers have targeted. He was a former tobacco chewer and he has been working to draw solutions to minimize the dependence on nicotine from last fifteen years.
Philip Lazarus, co-author of the paper, Boeing distinguished professor of pharmaceutical sciences, in collaboration with Denton have come up with various molecules that combine with CYP2A6 and prevents the ability to metabolize nicotine.
Lazarus also added by saying, that if one prevents CYP2A6 it should not affect one’s health. Targeting the specific enzyme is required. As it will possibly end or minimize smoking. Researchers have tested their candidate drugs that will not disrupt the major enzymes and the total number of potential drugs have reduce to 18.